HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya

Journal of Viral Hepatitis

Volumn 18, Issue 10, 2011, Pages

  Kim, H N ^a   Scott, J ^a   Cent, A ^b   Cook, L ^b,c   Morrow, R A ^b   Richardson, B ^b   Tapia, K ^b   Jerome, K R ^b,c   Lule, G ^d   John Stewart, G ^a,b   Chung, M H ^a,b,d  

^a Departments of Medicine   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

hepatitis B virus; HIV 1; lamivudine resistance

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; VIRUS CARRIER; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; KENYA; LAMIVUDINE; MALE; NEVIRAPINE; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80052852469     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01466.x     Document Type: Article

References (32)

1. Lavanchy D,. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008; 22 (6): 991-1008.
2. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-662.
3. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30 (5): 1302-1306. (Pubitemid 29510871)
4. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 2011; 8 (3): e1000422.
5. Emery S, Bodrug S, Richardson BA, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 2000; 38 (7): 2688-2695. (Pubitemid 30485151)
6. Curtis M, Zhu Y, Borroto-Esoda K,. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis 2007; 196 (10): 1483-1486. (Pubitemid 351411984)
7. Karatayli E, Karayalcin S, Karaaslan H, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007; 12 (5): 761-768. (Pubitemid 47235490)
8. Zollner B, Sterneck M, Wursthorn K, et al. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy. J Clin Microbiol 2005; 43 (5): 2503-2505. (Pubitemid 40656280)
9. Harania RS, Karuru J, Nelson M, Stebbing J,. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 2008; 22 (10): 1221-1222.
10. Ngure K, Mugo N, Musingila P, Irungu E,. Hepatitis B infection among HIV serodiscordant couples in Kenya. Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, S. Africa. July 19-22 of Conference 2009.
11. Christian B, Okuma J, Hawkins C, et al. Prevalence of hepatitis B and C co-infection and response to antiretroviral therapy among HIV-infected patients in an urban setting in Tanzania. Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA. February 16-19 of Conference 2010.
12. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45 (5): 624-632. (Pubitemid 47328645)
13. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48 (4): 1062-1069.
14. Kramvis A, Kew MC,. Molecular characterization of subgenotype A1 (subgroup Aa) of hepatitis B virus. Hepatol Res 2007; 37 (s1): S27-S32. (Pubitemid 47086512)
15. Idoko J, Meloni S, Muazu M, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49 (8): 1268-1273.
16. Rouet F, Chaix ML, Inwoley A, et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004; 74 (1): 34-40. (Pubitemid 38988857)
17. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20 (6): 863-870. (Pubitemid 43731568)
18. Chadwick D, Sarfo F, Ankcorn M, et al. Response to antiretroviral therapy in hepatitis B and HIV co-infected West Africans. Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA. February 16-19 of Conference 2010.
19. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL,. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34 (4 Pt 1): 785-791. (Pubitemid 32928004)
20. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36 (6): 687-696. (Pubitemid 36337972)
21. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32 (4 Pt 1): 828-834.
22. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42 (1): 121-129. (Pubitemid 40911319)
23. Chan HL, Wang H, Niu J, Chim AM, Sung JJ,. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12 (3): 345-353. (Pubitemid 46787979)
24. Wongprasit P, Manosuthi W, Kiertiburanakul S, Sungkanuparph S,. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy. AIDS Patient Care STDS 2010; 24 (4): 205-209.
25. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360 (9349): 1921-1926. (Pubitemid 35472132)
26. Sheng WH, Chen MY, Hsieh SM, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004; 38 (10): 1471-1477.
27. Omland LH, Weis N, Skinhoj P, et al. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study. HIV Med 2008; 9 (5): 300-306. (Pubitemid 351517277)
28. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48 (12): 1763-1771.
29. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19 (6): 593-601. (Pubitemid 40543982)
30. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166 (15): 1632-1641. (Pubitemid 44232373)
31. Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47 (11): 1479-1485.
32. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46 (1): 254-265. (Pubitemid 47171942)